SmithKline told to find partner
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SmithKline Beecham faces an uphill struggle to convince its shareholders that it should remain independent in the wake of the collapse of merger talks with fellow drugs giant Glaxo Wellcome.
A number of fund managers yesterday called on the group to seek other merger partners to recoup the value lost from the termination of the Glaxo deal.
Meanwhile, Glaxo Wellcome is to continue to lobby its shareholders to support a no-premium bid for SmithKline, despite the fact that institutions are divided on the merits of such a deal, it emerged yesterday.
Several large institutional shareholders are willing to support such a hostile bid, but others believe the potential obstacle of writing off pounds 45bn of goodwill which could result from a takeover is too much to overcome.
Glaxo has ruled out the idea of offering a large premium for SmithKline after an outcry from some of its largest shareholders which have indicated they would resist such a move. They are against such a bid as it will destroy much of the extra value that could result from a merger.
Glaxo's advisers are understood to be confident they can overcome the goodwill problem by structuring the deal to avoid liabilities.
Another idea suggested by investors would be to produce separate accounts, one stating the "clean" underlying earnings figures and another including the effect of goodwill write-offs.
"We want our pounds 15bn of value back and we will consider any way to get it," said one shareholder in both SmithKline and Glaxo. Both companies face a testing time over the coming weeks in their attempts to justify the breakdown in talks. It seems clear that the future of Jan Leschly, chief executive of SmithKline, and Sir Richard Sykes, chairman of Glaxo, will be called into doubt if they cannot give dispel the feeling among many institutions that the collapse of the merger had more to do with a clash of egos than management culture.
"If they cannot give us a good reason why this deal broke down we could call on the non-executives to assert their authority and maybe we could still get a merger," said one shareholder. However, other institutions believe all hopes for a deal are dead.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments